Close
CDMO Safety Testing 2026
Novotech

PHARMASEAL Launches Engility CTMS, an Innovative Clinical Trial Management Platform for Unified Governance­

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Novartis Expands Radioligand Therapy Manufacturing in US

Swiss pharmaceutical company Novartis has started construction of a...

Angelini Pharma Expands US Presence with Catalyst Pharmaceuticals Acquisition

Angelini Pharma has finalized a definitive agreement to acquire...

Are Glutathione Injections in NYC Worth It? A Complete Guide

When whatever you do to your skin makes it...
- Advertisement -

PHARMASEAL, anew provider of clinical trial management and governance solutions to enter the market, has launched Engility CTMS, the first product to be released from its Engility B2B platform.

With a focus on usability and rapid implementation, this innovative new generation clinical trial management system (CTMS) has been designed to increase the level of governance and control that organisations demand from their management systems to enable effective oversight of their clinical trials.

A key challenge to overcome in the design was to optimise the cost of software validation so that new innovations can be introduced easily for the benefit of customers. EngilityCTMS is engineered for change and benefits from extensive automation to deliver new features in a regulated industry,faster than current products. With an intuitive interface and a flexible cloud architecture, biopharmaceutical and medical device companies of all sizes can leverage affordable enterprise technology to fit their particular organisation model.

Commenting on the company’s introductionto the market and the launch of itsfoundation product EngilityCTMS, Daljit Cheema, CEO and Founderof PHARMASEAL said:  “We are extremely proud to finally launch our new company and release ourinnovativeCTMS product. Our collective passion for continuous innovation led to developing the Engility platformand our first product, EngilityCTMS.With Engility, we can enable more companies to improve their governance and oversight processes. PHARMASEAL has proven that by applying advanced engineering and automation, technology can streamline and consolidate complex trial management activities.

We are excited to introduce Engility to the world market.” For further information, please visit www.pharmaseal.co

About PHARMASEAL
PHARMASEAL was founded in 2016 by a team of industry leaders who share a vision to create smarter technologies and innovative products for the improvement of human health.  The company’s  firstproduct EngilityCTMS simplifies the management and control of clinical trials for biopharmaceutical and medical device companies. EngilityCTMS utilises advanced engineeringofferingenterprise management with rapid deployment, an intuitive user interface and interoperability with other eClinical applications to optimisetrial governance and oversight. Further information can be found at: www.pharmaseal.co

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Latest stories

Related stories

Novartis Expands Radioligand Therapy Manufacturing in US

Swiss pharmaceutical company Novartis has started construction of a...

Angelini Pharma Expands US Presence with Catalyst Pharmaceuticals Acquisition

Angelini Pharma has finalized a definitive agreement to acquire...

Are Glutathione Injections in NYC Worth It? A Complete Guide

When whatever you do to your skin makes it...

Fujifilm Advances Drug Discovery with New Cyclic Peptide Screening Platform

FUJIFILM Corporation has developed a new screening methodology aimed...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »